Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
Oncotarget. 2017 Jul 04;:
Authors: Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan SA, Barbieri E, Speleman F, Shohet J, Vandesompele J, Van Maerken T
Abstract Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy.